These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Pennsylvania
|
23-0993790
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
One Quaker Park, 901 E. Hector Street,
Conshohocken, Pennsylvania
|
19428 – 2380
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
x
|
Accelerated filer
¨
|
|||
Non-accelerated filer
¨
(Do not check if smaller reporting company)
|
Smaller reporting Company
¨
|
Number of Shares of Common Stock
Outstanding on March 31, 2014
|
13,226,717
|
|
Page
|
||
PART I.
|
|
FINANCIAL INFORMATION
|
|
Item 1.
|
|
Financial Statements (unaudited)
|
|
3
|
|||
|
4
|
||
|
5
|
||
|
6
|
||
|
7
|
||
Item 2.
|
|
19
|
|
Item 3.
|
|
24
|
|
Item 4.
|
|
25
|
|
PART II.
|
|
26
|
|
Item 1.
|
26
|
||
Item 2.
|
26
|
||
Item 6.
|
|
27
|
|
Signatures
|
27
|
Unaudited
|
||||||||
Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Net sales
|
$ | 181,674 | $ | 176,193 | ||||
Cost of goods sold
|
116,560 | 113,585 | ||||||
Gross profit
|
65,114 | 62,608 | ||||||
Selling, general and administrative expenses
|
45,741 | 45,197 | ||||||
Operating income
|
19,373 | 17,411 | ||||||
Other (expense) income, net
|
(473 | ) | 346 | |||||
Interest expense
|
(525 | ) | (744 | ) | ||||
Interest income
|
453 | 169 | ||||||
Income before taxes and equity in net income of associated companies
|
18,828 | 17,182 | ||||||
Taxes on income before equity in net income of associated companies
|
6,546 | 4,133 | ||||||
Income before equity in net income of associated companies
|
12,282 | 13,049 | ||||||
Equity in net income of associated companies
|
1,027 | 1,142 | ||||||
Net income
|
13,309 | 14,191 | ||||||
Less: Net income attributable to noncontrolling interest
|
579 | 572 | ||||||
Net income attributable to Quaker Chemical Corporation
|
$ | 12,730 | $ | 13,619 | ||||
Per share data:
|
||||||||
Net income attributable to Quaker Chemical Corporation Common Shareholders – basic
|
$ | 0.96 | $ | 1.04 | ||||
Net income attributable to Quaker Chemical Corporation Common Shareholders – diluted
|
$ | 0.96 | $ | 1.04 | ||||
Dividends declared
|
$ | 0.25 | $ | 0.245 |
Unaudited
|
||||||||
Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Net income
|
$ | 13,309 | $ | 14,191 | ||||
Other comprehensive income (loss), net of tax
|
||||||||
Currency translation adjustments
|
1,274 | (1,763 | ) | |||||
Defined benefit retirement plans
|
546 | 1,306 | ||||||
Unrealized gain on available-for-sale securities
|
69 | 432 | ||||||
Other comprehensive income (loss)
|
1,889 | (25 | ) | |||||
Comprehensive income
|
15,198 | 14,166 | ||||||
Less: comprehensive income attributable to noncontrolling interest
|
(783 | ) | (439 | ) | ||||
Comprehensive income attributable to Quaker Chemical Corporation
|
$ | 14,415 | $ | 13,727 |
|
|
Unaudited
|
|
|||||
|
|
March 31, 2014
|
|
|
December 31, 2013
|
|
||
ASSETS
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
60,450
|
|
|
$
|
68,492
|
|
Accounts receivable, net
|
|
|
178,945
|
|
|
|
165,629
|
|
Inventories
|
|
|
|
|
|
|
|
|
Raw materials and supplies
|
|
|
39,573
|
|
|
|
37,063
|
|
Work-in-process and finished goods
|
|
|
38,441
|
|
|
|
34,494
|
|
Prepaid expenses and other current assets
|
|
|
22,735
|
|
|
|
23,169
|
|
Total current assets
|
|
|
340,144
|
|
|
|
328,847
|
|
Property, plant and equipment, at cost
|
|
|
235,402
|
|
|
|
233,865
|
|
Less accumulated depreciation
|
|
|
(151,548
|
)
|
|
|
(148,377
|
)
|
Net property, plant and equipment
|
|
|
83,854
|
|
|
|
85,488
|
|
Goodwill
|
|
|
58,633
|
|
|
|
58,151
|
|
Other intangible assets, net
|
|
|
30,472
|
|
|
|
31,272
|
|
Investments in associated companies
|
|
|
20,494
|
|
|
|
19,397
|
|
Deferred income taxes
|
|
|
19,936
|
|
|
|
24,724
|
|
Other assets
|
|
|
36,174
|
|
|
|
36,267
|
|
Total assets
|
|
$
|
589,707
|
|
|
$
|
584,146
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Short-term borrowings and current portion of long-term debt
|
|
$
|
1,267
|
|
|
$
|
1,395
|
|
Accounts and other payables
|
|
|
81,367
|
|
|
|
75,580
|
|
Accrued compensation
|
|
|
12,188
|
|
|
|
20,801
|
|
Other current liabilities
|
|
|
33,141
|
|
|
|
33,080
|
|
Total current liabilities
|
|
|
127,963
|
|
|
|
130,856
|
|
Long-term debt
|
|
|
17,215
|
|
|
|
17,321
|
|
Deferred income taxes
|
|
|
6,459
|
|
|
|
6,729
|
|
Other non-current liabilities
|
|
|
80,062
|
|
|
|
84,544
|
|
Total liabilities
|
|
|
231,699
|
|
|
|
239,450
|
|
Equity
|
|
|
|
|
|
|
|
|
Common stock $1 par value; authorized 30,000,000 shares; issued and outstanding
|
|
|
|
|
|
|
|
|
2014 – 13,226,717 shares; 2013 – 13,196,140 shares
|
|
|
13,227
|
|
|
|
13,196
|
|
Capital in excess of par value
|
|
|
100,429
|
|
|
|
99,038
|
|
Retained earnings
|
|
|
267,707
|
|
|
|
258,285
|
|
Accumulated other comprehensive loss
|
|
|
(33,015
|
)
|
|
|
(34,700
|
)
|
Total Quaker shareholders’ equity
|
|
|
348,348
|
|
|
|
335,819
|
|
Noncontrolling interest
|
|
|
9,660
|
|
|
|
8,877
|
|
Total equity
|
|
|
358,008
|
|
|
|
344,696
|
|
Total liabilities and equity
|
|
$
|
589,707
|
|
|
$
|
584,146
|
|
|
Unaudited
|
|||||||
|
For the Three Months Ended
|
|||||||
|
March 31,
|
|||||||
|
2014
|
2013
|
||||||
Cash flows from operating activities
|
|
|
||||||
Net income
|
$ | 13,309 | $ | 14,191 | ||||
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
|
||||||||
Depreciation
|
3,075 | 3,056 | ||||||
Amortization
|
813 | 879 | ||||||
Equity in undistributed earnings of associated companies, net of dividends
|
(927 | ) | 921 | |||||
Deferred compensation and other, net
|
2,944 | (861 | ) | |||||
Stock-based compensation
|
1,388 | 1,040 | ||||||
Gain on disposal of property, plant and equipment
|
(48 | ) | (2 | ) | ||||
Insurance settlement realized
|
(337 | ) | — | |||||
Pension and other postretirement benefits
|
(1,665 | ) | (2,521 | ) | ||||
(Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions:
|
||||||||
Accounts receivable
|
(13,387 | ) | (3,977 | ) | ||||
Inventories
|
(6,389 | ) | (1,837 | ) | ||||
Prepaid expenses and other current assets
|
(29 | ) | (457 | ) | ||||
Accounts payable and accrued liabilities
|
(544 | ) | 874 | |||||
Net cash (used in) provided by operating activities
|
(1,797 | ) | 11,306 | |||||
|
||||||||
Cash flows from investing activities
|
||||||||
Investments in property, plant and equipment
|
(3,057 | ) | (2,723 | ) | ||||
Payments related to acquisitions, net of cash acquired
|
— | (647 | ) | |||||
Proceeds from disposition of assets
|
58 | 13 | ||||||
Insurance settlement interest earned
|
11 | 14 | ||||||
Change in restricted cash, net
|
326 | (14 | ) | |||||
Net cash used in investing activities
|
(2,662 | ) | (3,357 | ) | ||||
|
||||||||
Cash flows from financing activities
|
||||||||
Net increase in short-term borrowings
|
— | 594 | ||||||
Repayment of long-term debt
|
(232 | ) | (2,438 | ) | ||||
Dividends paid
|
(3,300 | ) | (3,208 | ) | ||||
Stock options exercised, other
|
(205 | ) | (59 | ) | ||||
Excess tax benefit related to stock option exercises
|
239 | 369 | ||||||
Net cash used in financing activities
|
(3,498 | ) | (4,742 | ) | ||||
Effect of exchange rate changes on cash
|
(85 | ) | (498 | ) | ||||
Net (decrease) increase in cash and cash equivalents
|
(8,042 | ) | 2,709 | |||||
Cash and cash equivalents at beginning of period
|
68,492 | 32,547 | ||||||
Cash and cash equivalents at end of period
|
$ | 60,450 | $ | 35,256 |
|
Three Months Ended
|
|||||||
|
March 31,
|
|||||||
|
2014
|
2013
|
||||||
Net sales
|
|
|
||||||
North America
|
$ | 76,716 | $ | 74,758 | ||||
EMEA
|
49,189 | 46,707 | ||||||
Asia/Pacific
|
41,937 | 37,988 | ||||||
South America
|
13,832 | 16,740 | ||||||
Total net sales
|
$ | 181,674 | $ | 176,193 | ||||
|
||||||||
Operating earnings, excluding indirect operating expenses
|
||||||||
North America
|
$ | 15,711 | $ | 15,039 | ||||
EMEA
|
8,096 | 6,970 | ||||||
Asia/Pacific
|
9,918 | 9,628 | ||||||
South America
|
1,509 | 2,875 | ||||||
Total operating earnings, excluding indirect operating expenses
|
35,234 | 34,512 | ||||||
Indirect operating expenses
|
(15,048 | ) | (16,222 | ) | ||||
Amortization expense
|
(813 | ) | (879 | ) | ||||
Consolidated operating income
|
19,373 | 17,411 | ||||||
Other (expense) income, net
|
(473 | ) | 346 | |||||
Interest expense
|
(525 | ) | (744 | ) | ||||
Interest income
|
453 | 169 | ||||||
Consolidated income before taxes and equity in net income of associated companies
|
$ | 18,828 | $ | 17,182 |
|
March 31,
|
|||||||
|
2014
|
2013
|
||||||
Stock options
|
$ | 150 | $ | 100 | ||||
Nonvested stock awards and restricted stock units
|
556 | 383 | ||||||
Employee stock purchase plan
|
17 | 12 | ||||||
Non-elective and elective 401(k) matching contribution in stock
|
649 | 525 | ||||||
Director stock ownership plan
|
16 | 20 | ||||||
Total share-based compensation expense
|
$ | 1,388 | $ | 1,040 |
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
Weighted Average
|
Remaining
|
||
|
Number of
|
|
Exercise Price per
|
Contractual
|
||
|
Shares
|
|
Share
|
Term (years)
|
||
Options outstanding at December 31, 2013
|
75,251
|
|
$
|
44.49
|
|
|
Options granted
|
37,048
|
|
|
73.47
|
|
|
Options exercised
|
(3,292)
|
|
|
42.24
|
|
|
Options outstanding at March 31, 2014
|
109,007
|
|
$
|
54.41
|
5.6
|
|
Options exercisable at March 31, 2014
|
39,897
|
|
$
|
39.64
|
4.5
|
|
|
|
|
|
|
|
Weighted
|
|
Weighted
|
|
Number
|
|
Weighted
|
|
||||
|
|
|
|
|
|
Number
|
Average
|
|
Average
|
|
Exercisable
|
|
Average
|
|
||||
Range of
|
Outstanding
|
Contractual
|
|
Exercise
|
|
at
|
|
Exercise
|
|
|||||||||
Exercise Prices
|
at 3/31/2014
|
Life
|
|
Price
|
|
3/31/2014
|
|
Price
|
|
|||||||||
$
|
0.00
|
-
|
|
$
|
10.00
|
—
|
—
|
|
$
|
—
|
|
—
|
|
$
|
—
|
|
||
$
|
10.01
|
-
|
|
$
|
20.00
|
6,155
|
2.8
|
|
|
18.82
|
|
6,155
|
|
|
18.82
|
|
||
$
|
20.01
|
-
|
|
$
|
30.00
|
—
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
||
$
|
30.01
|
-
|
|
$
|
40.00
|
35,020
|
4.6
|
|
|
37.87
|
|
23,954
|
|
|
37.75
|
|
||
$
|
40.01
|
-
|
|
$
|
50.00
|
2,192
|
5.2
|
|
|
46.21
|
|
731
|
|
|
46.21
|
|
||
$
|
50.01
|
-
|
|
$
|
60.00
|
28,592
|
5.9
|
|
|
58.26
|
|
9,057
|
|
|
58.26
|
|
||
$
|
60.01
|
-
|
|
$
|
70.00
|
—
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
||
$
|
70.01
|
-
|
|
$
|
80.00
|
37,048
|
6.9
|
|
|
73.47
|
|
—
|
|
|
—
|
|
||
|
|
|
|
|
|
109,007
|
5.6
|
|
|
54.41
|
|
39,897
|
|
|
39.64
|
|
|
2014
|
|
Number of options granted
|
37,048
|
|
Dividend Yield
|
2.00
|
%
|
Expected Volatility
|
43.34
|
%
|
Risk-free interest rate
|
1.22
|
%
|
Expected term (years)
|
4.0
|
|
|
|
|
Weighted
|
|
|
|
|
|
Average Grant
|
|
|
|
Number of
|
|
Date Fair Value
|
|
|
|
Shares
|
|
(per share)
|
|
|
Nonvested awards, December 31, 2013
|
115,984
|
|
$
|
47.27
|
|
Granted
|
22,656
|
|
$
|
73.37
|
|
Vested
|
(22,325)
|
|
$
|
38.44
|
|
Nonvested awards, March 31, 2014
|
116,315
|
|
$
|
54.05
|
|
|
|
|
Weighted
|
|
|
|
|
|
Average Grant
|
|
|
|
Number of
|
|
Date Fair Value
|
|
|
|
units
|
|
(per unit)
|
|
|
Nonvested awards, December 31, 2013
|
4,018
|
|
$
|
49.71
|
|
Granted
|
2,140
|
|
$
|
74.89
|
|
Nonvested awards, March 31, 2014
|
6,158
|
|
$
|
58.46
|
|
|
Three Months Ended March 31,
|
|||||||||||||
|
|
|
Other
|
|||||||||||
|
|
|
Postretirement
|
|||||||||||
|
Pension Benefits
|
Benefits
|
||||||||||||
|
2014
|
2013
|
2014
|
2013
|
||||||||||
Service cost
|
$ | 734 | $ | 838 | $ | 8 | $ | 13 | ||||||
Interest cost and other
|
1,542 | 1,380 | 54 | 56 | ||||||||||
Expected return on plan assets
|
(1,607 | ) | (1,478 | ) | — | — | ||||||||
Actuarial loss amortization
|
789 | 981 | 6 | 47 | ||||||||||
Prior service cost amortization
|
866 | 28 | — | — | ||||||||||
Net periodic benefit cost
|
$ | 2,324 | $ | 1,749 | $ | 68 | $ | 116 |
|
2014
|
2013
|
||||||
Income from third party license fees
|
$ | 298 | $ | 265 | ||||
Net foreign exchange (losses) gains
|
(799 | ) | 33 | |||||
Other non-operating income
|
83 | 97 | ||||||
Other non-operating expense
|
(55 | ) | (49 | ) | ||||
|
||||||||
Total other (expense) income, net
|
$ | (473 | ) | $ | 346 |
|
Three Months Ended March 31,
|
|||||||
|
2014
|
2013
|
||||||
Basic earnings per common share
|
|
|
||||||
|
|
|
||||||
Net income attributable to Quaker Chemical Corporation
|
$ | 12,730 | $ | 13,619 | ||||
Less: income allocated to participating securities
|
(112 | ) | (111 | ) | ||||
Net income available to common shareholders
|
$ | 12,618 | $ | 13,508 | ||||
Basic weighted average common shares outstanding
|
13,091,503 | 13,001,963 | ||||||
|
||||||||
Basic earnings per common share
|
$ | 0.96 | $ | 1.04 | ||||
|
||||||||
Diluted earnings per common share
|
||||||||
|
||||||||
Net income attributable to Quaker Chemical Corporation
|
$ | 12,730 | $ | 13,619 | ||||
Less: income allocated to participating securities
|
(112 | ) | (111 | ) | ||||
Net income available to common shareholders
|
$ | 12,618 | $ | 13,508 | ||||
Basic weighted average common shares outstanding
|
13,091,503 | 13,001,963 | ||||||
Effect of dilutive securities
|
19,649 | 29,937 | ||||||
Diluted weighted average common shares outstanding
|
13,111,152 | 13,031,900 | ||||||
|
||||||||
Diluted earnings per common share
|
$ | 0.96 | $ | 1.04 |
|
North
|
|
|
South
|
|
||||||||||
|
America
|
EMEA
|
Asia/Pacific
|
America
|
Total
|
||||||||||
Balance as of December 31, 2013
|
$ | 28,127 | $ | 11,184 | $ | 15,018 | $ | 3,822 | $ | 58,151 | |||||
Currency translation adjustments
|
193 | 108 | 144 | 37 | 482 | ||||||||||
Balance as of March 31, 2014
|
$ | 28,320 | $ | 11,292 | $ | 15,162 | $ | 3,859 | $ | 58,633 |
|
Gross Carrying
|
Accumulated
|
||||||||||||||
|
Amount
|
Amortization
|
||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Definite-lived intangible assets
|
|
|
|
|
||||||||||||
Customer lists and rights to sell
|
$ | 33,589 | $ | 33,559 | $ | 10,730 | $ | 10,221 | ||||||||
Trademarks and patents
|
6,837 | 6,838 | 3,366 | 3,202 | ||||||||||||
Formulations and product technology
|
5,808 | 5,808 | 3,756 | 3,709 | ||||||||||||
Other
|
5,544 | 5,544 | 4,554 | 4,445 | ||||||||||||
Total
|
$ | 51,778 | $ | 51,749 | $ | 22,406 | $ | 21,577 |
For the year ended December 31, 2014
|
$ | 3,252 | ||
For the year ended December 31, 2015
|
$ | 3,252 | ||
For the year ended December 31, 2016
|
$ | 2,778 | ||
For the year ended December 31, 2017
|
$ | 2,119 | ||
For the year ended December 31, 2018
|
$ | 2,095 | ||
For the year ended December 31, 2019
|
$ | 2,095 |
|
|
|
|
Accumulated
|
|
|
||||||||||||||||||
|
|
Capital in
|
|
Other
|
|
|
||||||||||||||||||
|
Common
|
excess of
|
Retained
|
Comprehensive
|
Noncontrolling
|
|
||||||||||||||||||
|
stock
|
par value
|
earnings
|
Loss
|
interest
|
Total
|
||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||
Balance at December 31, 2013
|
$ | 13,196 | $ | 99,038 | $ | 258,285 | $ | (34,700 | ) | $ | 8,877 | $ | 344,696 | |||||||||||
Net income
|
— | — | 12,730 | — | 579 | 13,309 | ||||||||||||||||||
Amounts reported in other comprehensive income
|
— | — | — | 1,685 | 204 | 1,889 | ||||||||||||||||||
Dividends ($0.25 per share)
|
— | — | (3,308 | ) | — | — | (3,308 | ) | ||||||||||||||||
Share issuance and equity-based compensation plans
|
31 | 1,152 | — | — | — | 1,183 | ||||||||||||||||||
Excess tax benefit from stock option exercises
|
— | 239 | — | — | — | 239 | ||||||||||||||||||
Balance at March 31, 2014
|
$ | 13,227 | $ | 100,429 | $ | 267,707 | $ | (33,015 | ) | $ | 9,660 | $ | 358,008 | |||||||||||
|
||||||||||||||||||||||||
Balance at December 31, 2012
|
$ | 13,095 | $ | 94,470 | $ | 215,390 | $ | (41,855 | ) | $ | 8,576 | $ | 289,676 | |||||||||||
Net income
|
— | — | 13,619 | — | 572 | 14,191 | ||||||||||||||||||
Amounts reported in other comprehensive income (loss)
|
— | — | — | 108 | (133 | ) | (25 | ) | ||||||||||||||||
Dividends ($0.245 per share)
|
— | — | (3,219 | ) | — | — | (3,219 | ) | ||||||||||||||||
Share issuance and equity-based compensation plans
|
45 | 936 | — | — | — | 981 | ||||||||||||||||||
Excess tax benefit from stock option exercises
|
— | 369 | — | — | — | 369 | ||||||||||||||||||
Balance at March 31, 2013
|
$ | 13,140 | $ | 95,775 | $ | 225,790 | $ | (41,747 | ) | $ | 9,015 | $ | 301,973 |
|
|
|
Unrealized
|
|
||||||||||||
|
Currency
|
Defined
|
gain (loss) in
|
|
||||||||||||
|
translation
|
benefit
|
available-for-
|
|
||||||||||||
|
adjustments
|
pension plans
|
sale securities
|
Total
|
||||||||||||
Balance at December 31, 2013
|
$ | 1,152 | $ | (37,433 | ) | $ | 1,581 | $ | (34,700 | ) | ||||||
Other comprehensive income before reclassifications
|
1,070 | 25 | 663 | 1,758 | ||||||||||||
Amounts reclassified from AOCI
|
— | 769 | (558 | ) | 211 | |||||||||||
Current period other comprehensive income
|
1,070 | 794 | 105 | 1,969 | ||||||||||||
Related tax amounts
|
— | (248 | ) | (36 | ) | (284 | ) | |||||||||
Net current period other comprehensive income
|
1,070 | 546 | 69 | 1,685 | ||||||||||||
Balance at March 31, 2014
|
$ | 2,222 | $ | (36,887 | ) | $ | 1,650 | $ | (33,015 | ) | ||||||
|
||||||||||||||||
Balance at December 31, 2012
|
$ | 3,336 | $ | (46,914 | ) | $ | 1,723 | $ | (41,855 | ) | ||||||
Other comprehensive (loss) income before reclassifications
|
(1,630 | ) | 762 | 1,148 | 280 | |||||||||||
Amounts reclassified from AOCI
|
— | 1,056 | (494 | ) | 562 | |||||||||||
Current period other comprehensive (loss) income
|
(1,630 | ) | 1,818 | 654 | 842 | |||||||||||
Related tax amounts
|
— | (512 | ) | (222 | ) | (734 | ) | |||||||||
Net current period other comprehensive (loss) income
|
(1,630 | ) | 1,306 | 432 | 108 | |||||||||||
Balance at March 31, 2013
|
$ | 1,706 | $ | (45,608 | ) | $ | 2,155 | $ | (41,747 | ) |
|
|
Fair Value Measurements at March 31, 2014
|
||||||||||||||
|
Fair Value
|
Using Fair Value Hierarchy
|
||||||||||||||
|
as of
|
|
|
|
||||||||||||
Assets
|
March 31, 2014
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Company-owned life insurance
|
$ | 1,913 | $ | — | $ | 1,913 | $ | — | ||||||||
Company-owned life insurance - Deferred compensation assets
|
334 | — | 334 | — | ||||||||||||
Other deferred compensation assets
|
||||||||||||||||
Large capitalization registered investment companies
|
65 | 65 | — | — | ||||||||||||
Mid capitalization registered investment companies
|
6 | 6 | — | — | ||||||||||||
Small capitalization registered investment companies
|
13 | 13 | — | — | ||||||||||||
International developed and emerging markets registered investment
|
||||||||||||||||
companies
|
39 | 39 | — | — | ||||||||||||
Fixed income registered investment companies
|
7 | 7 | — | — | ||||||||||||
|
||||||||||||||||
Total
|
$ | 2,377 | $ | 130 | $ | 2,247 | $ | — |
|
|
Fair Value Measurements at March 31, 2014
|
||||||||||||||
|
Fair Value
|
Using Fair Value Hierarchy
|
||||||||||||||
|
as of
|
|
|
|
||||||||||||
Liabilities
|
March 31, 2014
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Deferred compensation liabilities
|
|
|
|
|
||||||||||||
Large capitalization registered investment companies
|
$ | 370 | $ | 370 | $ | — | $ | — | ||||||||
Mid capitalization registered investment companies
|
103 | 103 | — | — | ||||||||||||
Small capitalization registered investment companies
|
87 | 87 | — | — | ||||||||||||
International developed and emerging markets registered investment
|
||||||||||||||||
companies
|
190 | 190 | — | — | ||||||||||||
Fixed income registered investment companies
|
40 | 40 | — | — | ||||||||||||
Fixed general account
|
155 | — | 155 | — | ||||||||||||
Acquisition-related consideration
|
4,830 | — | — | 4,830 | ||||||||||||
|
||||||||||||||||
Total
|
$ | 5,775 | $ | 790 | $ | 155 | $ | 4,830 |
|
|
Fair Value Measurements at December 31, 2013
|
||||||||||||||
|
Fair Value
|
Using Fair Value Hierarchy
|
||||||||||||||
|
as of
|
|
|
|
||||||||||||
Assets
|
December 31, 2013
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Company-owned life insurance
|
$ | 1,885 | $ | — | $ | 1,885 | $ | — | ||||||||
Company-owned life insurance - Deferred compensation assets
|
409 | — | 409 | — | ||||||||||||
Other deferred compensation assets
|
||||||||||||||||
Large capitalization registered investment companies
|
74 | 74 | — | — | ||||||||||||
Mid capitalization registered investment companies
|
6 | 6 | — | — | ||||||||||||
Small capitalization registered investment companies
|
13 | 13 | — | — | ||||||||||||
International developed and emerging markets registered investment
|
||||||||||||||||
companies
|
40 | 40 | — | — | ||||||||||||
Fixed income registered investment companies
|
7 | 7 | — | — | ||||||||||||
|
||||||||||||||||
Total
|
$ | 2,434 | $ | 140 | $ | 2,294 | $ | — |
|
|
Fair Value Measurements at December 31, 2013
|
||||||||||||||
|
Fair Value
|
Using Fair Value Hierarchy
|
||||||||||||||
|
as of
|
|
|
|
||||||||||||
Liabilities
|
December 31, 2013
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Deferred compensation liabilities
|
|
|
|
|
||||||||||||
Large capitalization registered investment companies
|
$ | 405 | $ | 405 | $ | — | $ | — | ||||||||
Mid capitalization registered investment companies
|
109 | 109 | — | — | ||||||||||||
Small capitalization registered investment companies
|
95 | 95 | — | — | ||||||||||||
International developed and emerging markets registered investment
|
||||||||||||||||
companies
|
205 | 205 | — | — | ||||||||||||
Fixed income registered investment companies
|
43 | 43 | — | — | ||||||||||||
Fixed general account
|
167 | — | 167 | — | ||||||||||||
Acquisition-related consideration
|
4,876 | — | — | 4,876 | ||||||||||||
|
||||||||||||||||
Total
|
$ | 5,900 | $ | 857 | $ | 167 | $ | 4,876 |
|
|
Non-competition
|
|
|||||||||
|
Earnout
|
Agreement
|
|
|||||||||
|
Summit
|
Obligation
|
Total
|
|||||||||
Balance at December 31, 2013
|
$ | 4,697 | $ | 179 | $ | 4,876 | ||||||
Interest accretion
|
12 | 4 | 16 | |||||||||
Payments
|
— | (62 | ) | (62 | ) | |||||||
Balance at March 31, 2014
|
$ | 4,709 | $ | 121 | $ | 4,830 |
|
Fair value at March 31, 2014
|
Valuation technique
|
Unobservable input
|
Input value
|
|||||
Summit earnout
|
$ | 4,709 |
Discounted cash flow
|
Discount rate
|
14.5 | % | |||
Non-competition agreement obligation
|
$ | 121 |
Discounted cash flow
|
Discount rate
|
14.0 | % |
|
Three Months Ended
|
|||||||
|
March 31,
|
|||||||
|
2014
|
2013
|
||||||
GAAP earnings per diluted share attributable to Quaker Chemical Corporation Common Shareholders
|
$ | 0.96 | $ | 1.04 | ||||
|
||||||||
Equity income in a captive insurance company per diluted share
|
(0.06 | ) | (0.11 | ) | ||||
UK pension plan amendment per diluted share
|
0.05 | — | ||||||
Devaluation of the Venezuelan Bolivar Fuerte per diluted share
|
— | 0.03 | ||||||
|
||||||||
Non-GAAP earnings per diluted share
|
$ | 0.95 | $ | 0.96 |
|
Three Months Ended
|
|||||||
|
March 31,
|
|||||||
|
2014
|
2013
|
||||||
Net income attributable to Quaker Chemical Corporation
|
$ | 12,730 | $ | 13,619 | ||||
Depreciation and amortization
|
3,888 | 3,935 | ||||||
Interest expense
|
525 | 744 | ||||||
Taxes on income before equity in net income of associated companies
|
6,546 | 4,133 | ||||||
Equity income in a captive insurance company
|
(846 | ) | (1,435 | ) | ||||
UK pension plan amendment
|
902 | — | ||||||
Devaluation of the Venezuelan Bolivar Fuerte
|
— | 357 | ||||||
|
||||||||
Adjusted EBITDA
|
$ | 23,745 | $ | 21,353 |
·
|
statements relating to our business strategy;
|
·
|
our current and future results and plans; and
|
·
|
statements that include the words “may,” “could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan” or similar expressions.
|
|
|
|
(c)
|
(d)
|
||||||||||||
|
|
|
Total Number of
|
Maximum
|
||||||||||||
|
|
|
Shares Purchased as
|
Number of Shares that
|
||||||||||||
|
(a)
|
(b)
|
Part of
|
May Yet
|
||||||||||||
|
Total Number
|
Average
|
Publicly Announced
|
Be Purchased Under the
|
||||||||||||
|
of Shares
|
Price Paid
|
Plans
|
Plans or
|
||||||||||||
Period
|
Purchased (1)
|
Per Share (2)
|
or Programs (3)
|
Programs (3)
|
||||||||||||
January 1 - January 31
|
— | $ | — | — | 252,600 | |||||||||||
February 1 - February 28
|
— | $ | — | — | 252,600 | |||||||||||
March 1 - March 31
|
5,708 | $ | 77.28 | — | 252,600 | |||||||||||
|
||||||||||||||||
Total
|
5,708 | $ | 77.28 | — | 252,600 |
(1)
|
All of the 5,708
shares acquired by the Company during the period covered by this report were acquired from employees upon their surrender of previously owned shares in payment of the exercise price of employee stock options exercised, for the payment of taxes upon exercise of employee stock options or for the vesting of restricted stock.
|
(2)
|
The price per share, in each case, represented the closing price of the Company’s common stock on the date of exercise or vesting, as specified by the plan pursuant to which the applicable option or restricted stock was granted.
|
(3)
|
On February 15, 1995, the Board of Directors of the Company authorized a share repurchase program authorizing the repurchase of up to 500,000 shares of Quaker common stock, and, on January 26, 2005, the Board authorized the repurchase of up to an additional 225,000 shares. Under the 1995 action of the Board, 27,600 shares may yet be purchased. Under the 2005 action of the Board, none of the shares authorized has been purchased and, accordingly, all of those shares may yet be purchased. Neither of the share repurchase authorizations has an expiration date.
|
(a) Exhibits
|
||||
10.1
|
–
|
|||
31.1
|
–
|
|||
31.2
|
–
|
|||
32.1
|
–
|
|||
32.2
|
–
|
|||
101.INS
|
–
|
XBRL Instance Document
|
||
101.SCH
|
–
|
XBRL Extension Schema Document
|
||
101.CAL
|
–
|
XBRL Calculation Linkbase Document
|
||
101.DEF
|
–
|
XBRL Definition Linkbase Document
|
||
101.LAB
|
–
|
XBRL Label Linkbase Document
|
||
101.PRE
|
–
|
XBRL Presentation Linkbase Document
|
*
|
This exhibit is a management contract or compensation plan or arrangement required to be filed as an exhibit.
|
QUAKER CHEMICAL CORPORATION
(Registrant)
|
||||
/s/ Margaret M. Loebl
|
||||
Date: April 29, 2014
|
Margaret M. Loebl, Vice President, Chief Financial Officer and Treasurer (officer duly authorized on behalf of, and principal financial officer of, the Registrant)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
Steelcase Inc. | SCS |
V.F. Corporation | VFC |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|